ZIMMER BIOMET HOLDINGS INC
For the period ended Mar 31, 2025. Filed May 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Unregistered Sales of Equity Securities
During the three-month period ended March 31, 2025, we issued 0.3 million shares of our common stock valued at $27.8 million upon the achievement of a commercial milestone related to the Embody acquisition. The shares were issued to the former Embody shareholders whom we reasonably believed to be accredited investors in a private transaction exempt from registration under Section 4(a)(2) and Regulation D under the Securities Act.
Issuer Purchases of Equity Securities
The following table summarizes repurchases of common stock settled during the three-month period ended March 31, 2025:
| Period · Total Number of Shares Purchased · Average Price Paid per Share · Total Number of Shares Purchased as a Part of Publicly Announced Program(1) · Maximum Approximate Dollar Value of Shares that may yet bePurchased Under the Program(1) | |||||
|---|---|---|---|---|---|
| January 2025 | - | $ | - | - | $1,249,999,420 |
| February 2025 | 837,755 | 103.27 | 837,755 | 1,163,483,012 | |
| March 2025 | 1,322,553 | 108.32 | 1,322,553 | 1,020,224,454 | |
| Total | 2,160,308 | $106.36 | 2,160,308 | 1,020,224,454 | |
(1) In May 2024, our Board of Directors authorized a $2.0 billion share repurchase program with no expiration date.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.